Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative Allogeneic Transplant After Prior Autologous Transplant
NCT00053196Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2002
- Primary completion
- Nov 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan in hematologic malignancy, leukemia, lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), sponsored by Cancer and Leukemia Group B. Started Dec 2002; status: completed.
02
Drugs
fludarabinebusulfan
03
Conditions
hematologic malignancyleukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00053196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053196.